Covid-19: Pharma exports may take a $1.5 billion hit

G Naga Sridhar Hyderabad | Updated on April 03, 2020 Published on April 03, 2020

‘Extension of lockdown will prove costly for sector’

The Covid-19 pandemic and the lockdown have adversely impacted pharmaceutical exports to the tune of $1.5- $2 billion.

“Pharmaceutical exports stood at $18.75 billion at the end of February with 10.7 per cent year-on-year growth,” R Uday Bhaskar, Director-General, Pharmaceutical Export Promotion Council (Pharmexcil), told BusinessLine on Friday.

But due to restrictions on export of some categories of drugs and the lockdown that has restricted the movement of goods, pharma exports have almost stopped from March 3. The government banned exports of about 26 APIs and formulations in the beginning of March.

“As a result, exports will not reach $22 billion as expected and the full-year figure will only be in the range of what has been achieved in the previous financial year,”' the DG said. During FY 19, total pharma exports stood at $19.14 billion.

The loss due to Covid-19 control measures was mainly in March and could be to the tune of $1.5-$2 billion, going by pharmexcil data. Pharma exports per month are about $1.6 billion throughout the financial year 2019-20, and March would generally see a higher quantum.

It may be recalled that bucking a recessionary trend, pharmaceutical exports registered the highest-ever year-on-year growth in the third quarter ended December 31, 2019, at 14.64 per cent.

During the April-February 2020 period (11 months), too, the overall growth was significantly higher. For instance, exports to the US showed an increase of nearly 19 per cent compared with the previous year.

According to a senior executive of a Hyderabad-based listed pharma company, any further extension of the lockdown could prove costly for the sector.

On behalf of exporters, Pharmexcil had also submitted a representation to the Director General of Foreign Trade to lift restrictions on exports.

Published on April 03, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.